Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform-Reference-Cited by-同舟云学术

Targeting by affinity–matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform

Published:1997-11 Issue:12 Volume:15 Page:1271-1275
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Neri Dario,Carnemolla Barbara,Nissim Ahuva,Leprini Alessandra,Querzè Germano,Balza Enrica,Pini Alessandro,Tarli Lorenzo,Halin Cornelia,Neri Paolo,Zardi Luciano,Winter Greg

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/nbt1197-1271.pdf

Reference46 articles.

1. Berkower, I. 1996. The promise and pitfalls of monoclonal antibody therapeutics. Curr. Opin. Biotechnol. 7: 622–628.

2. Press, O.W., Eary, J.F., Appelbaum, F.R., Martin, P.J., Nelp, W.B., Glen, S., et al. 1995. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autolo-gous stem cell transplantation for relapsed B cell lymphomas. Lancet 346: 336–340.

3. Riva, P., Arista, A., Tison, V., Sturiale, C., Franceschi, G., Spinelli, A. et al. 1994. Intralesional radio-immunotherapy of malignant gliomas. Cancer 73: 1076–1082.

4. Schneider-Gadicke, E. and Riethmüller, G. 1995. Prevention of manifest metastasis with monoclonal antibodies: a novel approach to immunotherapy of solid tumors. Eur. J. Cancer 31: 1326–1330.

5. Maloney, D.G., Liles, T.M., Czerwinski, D.K., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., and Levy, R. 1994. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84: 2457–2466.

Cited by 257 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. References;The Evolution of Immunotherapy Against Tumors;2025

2. Tumor-Homing Antibody-Cytokine Fusions for Cancer Therapy;OncoTargets and Therapy;2024-08

3. Cathepsin B Nuclear Flux in a DNA-Guided “Antinuclear Missile” Cancer Therapy;ACS Central Science;2024-07-15

4. Development of a modularized aptamer targeting the nuclear T-cell suppressor PAC1;The Analyst;2023

5. Intratumorally anchored cytokine therapy;Expert Opinion on Drug Delivery;2022-06-02